Alison Lawton is an executive leader with over 35 years of experience in the biopharma industry.  She was president and CEO of Kaleido Biosciences (KLDO), chief operating officer of Aura Biosciences, and fractional Chief Operating Officer at X4 Pharmaceuticals. Prior to that, Ms. Lawton spent more than 20 years in various positions of increasing responsibility at Genzyme, and subsequently at Sanofi (following the acquisition of Genzyme by Sanofi in 2011) including as General Manager of Genzyme Biosurgery (a ~$1Billion annual revenue business) and as senior vice president of Global Market Access & Regulatory Affairs for Genzyme.

Alison currently serves as Chair of the Board of Directors for Dianthus Therapeutics (DNTH); as an independent director for the public companies ProQR Therapeutics (PRQR) and X4 Pharmaceuticals (XFOR); and a member of the board of BlueRock Therapeutics.  She previously served as Chair of the board for Magenta Therapeutics (MGTA), and as a non-executive director of Aeglea (AGLE), Kaleido Biosciences (KLDO), Verastem (VSTM), CoLucid (CLCD) until its acquisition by Eli Lilly, and Cubist Pharmaceuticals (CBST) until its acquisition by Merck & Co. She was chair of the Board of the Regulatory Affairs Professional Society and the industry representative on the FDA Cell and Gene Therapy Advisory Committee. She earned a First Class BSc in Pharmacology, from King’s College, London University.